Prognostic Lysosome-Related Biomarkers for Predicting Drug Candidates in Hepatocellular Carcinoma: An Insilco Analysis

References

• Song Q, Meng B, Xu H, Mao Z. The emerging roles of vacuolar-type ATPase-dependent lysosomal acidification in neurodegenerative diseases. Transl Neurodegener. 2020;9(1):17. doi:10.1186/s40035-020-00196-0
   PubMed Web of Science ®Google Scholar
• Mahapatra KK, Panigrahi DP, Praharaj PP, et al. Molecular interplay of autophagy and endocytosis in human health and diseases. Biol Rev Camb Philos Soc. 2019;94(4):1576–1590. doi:10.1111/brv.12515
   PubMed Web of Science ®Google Scholar
• Zhao B, Dierichs L, Gu JN, et al. TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancer. Cell Death Discov. 2020;6:12. doi:10.1038/s41420-020-0246-7
   PubMed Web of Science ®Google Scholar
• Di malta C, Cinque L, Settembre C. Transcriptional regulation of autophagy: mechanisms and diseases. Front Cell Dev Biol. 2019;7:114.
   PubMed Web of Science ®Google Scholar
• Aits S, Jäättelä M. Lysosomal cell death at a glance. J Cell Sci. 2013;126(Pt 9):1905–1912.
   PubMed Web of Science ®Google Scholar
• Domagala A, Fidyt K, Bobrowicz M, Stachura J, Szczygiel K, Firczuk M. Typical and atypical inducers of lysosomal cell death: a promising anticancer strategy. Int J Mol Sci. 2018;19(8):2256.
   PubMed Web of Science ®Google Scholar
• Jahreiss L, Menzies FM, Rubinsztein DC. The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes. Traffic. 2008;9(4):574–587.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang Q, Song D, et al. Lysosomal dysfunction and autophagy blockade contribute to autophagy-related cancer suppressing peptide-induced cytotoxic death of cervical cancer cells through the AMPK/mTOR pathway. J Exp Clin Cancer Res. 2020;39(1):197.
   PubMed Web of Science ®Google Scholar
• Elimam H, El-Say KM, Cybulsky AV, Khalil H. Regulation of autophagy progress via lysosomal depletion by fluvastatin nanoparticle treatment in breast cancer cells. ACS omega. 2020;5(25):15476–15486.
   PubMed Web of Science ®Google Scholar
• Zhitomirsky B, Assaraf YG. Lysosomes as mediators of drug resistance in cancer. Drug Resist Updat. 2016;24:23–33. doi:10.1016/j.drup.2015.11.004
   PubMed Web of Science ®Google Scholar
• Breinig M, Caldas-Lopes E, Goeppert B, et al. Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology. 2009;50(1):102–112. doi:10.1002/hep.22912
   PubMed Web of Science ®Google Scholar
• Suzuki S, Ogawa M, Miyazaki M, et al. Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells. Oncol Rep. 2022;47(2):1–20.
   PubMed Web of Science ®Google Scholar
• Ferro I, Gavini J, Gallo S, et al. The human vault RNA enhances tumorigenesis and chemoresistance through the lysosome in hepatocellular carcinoma. Autophagy. 2022;18(1):191–203. doi:10.1080/15548627.2021.1922983
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yue P, Lu T, Wang Y, Wei Y, Wei X. Role of lysosomes in physiological activities, diseases, and therapy. J Hematol Oncol. 2021;14(1):79.
   PubMed Web of Science ®Google Scholar
• Qi C, Zou L, Wang S, et al. Vps34 inhibits hepatocellular carcinoma invasion by regulating endosome-lysosome trafficking via Rab7-RILP and Rab11. Cancer Res Treat. 2022;54(1):182–198. doi:10.4143/crt.2020.578
   PubMed Web of Science ®Google Scholar
• Brun S, Bestion E, Raymond E, et al. GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions. Autophagy. 2022;18(3):678–694. doi:10.1080/15548627.2021.1988357
   PubMed Web of Science ®Google Scholar
• Siow WX, Kabiri Y, Tang R, et al. Lysosomal TRPML1 regulates mitochondrial function in hepatocellular carcinoma cells. J Cell Sci. 2022;135(6). doi:10.1242/jcs.259455
   PubMed Web of Science ®Google Scholar
• Che L, Wu JS, Xu CY, et al. Protein phosphatase 2A-B56γ-Drp1-Rab7 signaling axis regulates mitochondria-lysosome crosstalk to sensitize the anti-cancer therapy of hepatocellular carcinoma. Biochem Pharmacol. 2022;202:115132. doi:10.1016/j.bcp.2022.115132
   PubMed Web of Science ®Google Scholar
• Zhang G. Platelet-related molecular subtype to predict prognosis in hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:423–436. doi:10.2147/JHC.S363200
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18(1):220. doi:10.1186/s13059-017-1349-1
   PubMed Web of Science ®Google Scholar
• Zhu K, Xiaoqiang L, Deng W, Wang G, Fu B. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer. Lipids Health Dis. 2021;20(1):146. doi:10.1186/s12944-021-01554-1
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Reinhold WC, Sunshine M, Liu H, et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 2012;72(14):3499–3511. doi:10.1158/0008-5472.CAN-12-1370
   PubMed Web of Science ®Google Scholar
• Zhang G. Regulatory T-cells-related signature for identifying a prognostic subtype of hepatocellular carcinoma with an exhausted tumor microenvironment. Front Immunol. 2022;13:975762. doi:10.3389/fimmu.2022.975762
   PubMed Web of Science ®Google Scholar
• Zhang G, Lv X, Yang Q, Liu H. Identification of HM13 as a prognostic indicator and a predictive biomarker for immunotherapy in hepatocellular carcinoma. BMC Cancer. 2022;22(1):888. doi:10.1186/s12885-022-09987-2
   PubMed Web of Science ®Google Scholar
• Colwill K, Gräslund S. A roadmap to generate renewable protein binders to the human proteome. Nat Methods. 2011;8(7):551–558. doi:10.1038/nmeth.1607
   PubMed Web of Science ®Google Scholar
• Mondal B, Dutta T, Padhy A, Das S, Sen Gupta S. Lysosome-targeting strategy using polypeptides and chimeric molecules. ACS omega. 2022;7(1):5–16. doi:10.1021/acsomega.1c04771
   PubMed Web of Science ®Google Scholar
• Wang N, Liu H, Liu G, et al. Yeast β-D-glucan exerts antitumour activity in liver cancer through impairing autophagy and lysosomal function, promoting reactive oxygen species production and apoptosis. Redox Biol. 2020;32:101495. doi:10.1016/j.redox.2020.101495
   PubMed Web of Science ®Google Scholar
• Fu Y, Gu Q, Luo L, et al. New anti-cancer strategy to suppress colorectal cancer growth through inhibition of ATG4B and lysosome function. Cancers. 2020;12(6). doi:10.3390/cancers12061523
   Web of Science ®Google Scholar
• Ketchesin KD, Stinnett GS, Seasholtz AF. Corticotropin-releasing hormone-binding protein and stress: from invertebrates to humans. Stress. 2017;20(5):449–464. doi:10.1080/10253890.2017.1322575
   PubMed Web of Science ®Google Scholar
• Deng F, Shen L, Wang H, Zhang L. Classify multicategory outcome in patients with lung adenocarcinoma using clinical, transcriptomic and clinico-transcriptomic data: machine learning versus multinomial models. Am J Cancer Res. 2020;10(12):4624–4639.
   PubMed Web of Science ®Google Scholar
• Yang K, Xiao Y, Xu T, et al. Integrative analysis reveals CRHBP inhibits renal cell carcinoma progression by regulating inflammation and apoptosis. Cancer Gene Ther. 2020;27(7–8):607–618.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lei L, Chi YG, Liu LB, Yang BP. A comprehensive understanding of ovarian carcinoma survival prognosis by novel biomarkers. Eur Rev Med Pharmacol Sci. 2019;23(19):8257–8264.
   PubMed Web of Science ®Google Scholar
• Wang Z, Li M, Liu Y, et al. CRHBP is degraded via autophagy and exerts anti-hepatocellular carcinoma effects by reducing cyclin B2 expression and dissociating cyclin B2-CDK1 complex. Cancer Gene Ther. 2022;29(8–9):1217–1227.
   PubMed Web of Science ®Google Scholar
• Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557–4566.
   PubMed Web of Science ®Google Scholar
• Hou PP, Luo LJ, Chen HZ, et al. Ectosomal PKM2 promotes HCC by inducing macrophage differentiation and remodeling the tumor microenvironment. Mol Cell. 2020;78(6):1192–1206.e1110.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang X, Zheng L, et al. RIPK3 orchestrates fatty acid metabolism in tumor-associated macrophages and hepatocarcinogenesis. Cancer Immunol Res. 2020;8(5):710–721.
   PubMed Web of Science ®Google Scholar
• Cui C, Chakraborty K, Tang XA, et al. A lysosome-targeted DNA nanodevice selectively targets macrophages to attenuate tumours. Nat Nanotechnol. 2021;16(12):1394–1402.
   PubMed Web of Science ®Google Scholar
• Carbone C, Piro G, Agostini A, et al. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer. J Immunother Cancer. 2021;9:9.
   Web of Science ®Google Scholar
• Li YP, Chen JJ, Shen JJ, et al. Synthesis and biological evaluation of geldanamycin analogs against human cancer cells. Cancer Chemother Pharmacol. 2015;75(4):773–782.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li HM, Zhou C, et al. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells. J Exp Clin Cancer Res. 2016;35(1):149.
   PubMedGoogle Scholar
• Xie Y, Guo L, Huang J, et al. Cyclopentenone-containing tetrahydroquinoline and geldanamycin alkaloids from streptomyces malaysiensis as potential anti-androgens against prostate cancer cells. J Nat Prod. 2021;84(7):2004–2011.
   PubMed Web of Science ®Google Scholar
• Xing R, Gao J, Cui Q, Wang Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021;12:783236.
   PubMed Web of Science ®Google Scholar